“Readily Available” Means Practically Obtainable—Not FDA-Approved: Contract Plain-Meaning Limits in Georgia’s Execution-Resumption Agreement

1. Introduction

STATE OF GEORGIA et al. v. FEDERAL DEFENDER PROGRAM, INC. et al. is the Supreme Court of Georgia’s second major decision interpreting a pandemic-era written agreement (formed via email exchange) governing when the State would resume seeking execution warrants for a defined group of death-sentenced inmates after COVID-19.

The plaintiffs/appellees included the Federal Defender Program, Inc. (and later intervenors, including death-row inmate Virgil Delano Presnell, Jr. and a capital-defense resource organization). The defendants/appellants were the State of Georgia and the Attorney General in his official capacity.

The core dispute in this appeal concerned one contractual prerequisite to the Attorney General’s office pursuing execution warrants from district attorneys: whether “a vaccination against COVID19 is readily available to all members of the public” (the “Vaccine Condition”). The trial court held that the condition was unsatisfied because the FDA had not approved COVID-19 vaccines for children under six months old, and it entered a permanent injunction tied to that conclusion.

The Supreme Court reversed, holding that the trial court impermissibly added an FDA-approval requirement to the contract’s text. The Court also resolved a threshold appellate-jurisdiction issue under Georgia’s Prison Litigation Reform Act (PLRA), rejecting the argument that a prisoner’s intervention converted the case into an “action filed by a prisoner” requiring discretionary appeal.

2. Summary of the Opinion

  • PLRA jurisdiction: The Court held the appeal was properly taken as a direct appeal because this case was not an “action filed by a prisoner” within OCGA § 42-12-8; Presnell intervened but did not “file” the action, and an intervention motion in an existing civil suit is not itself an “action.”
  • Law of the case: The Court reaffirmed that its prior legal ruling in State v. Fed. Defender Program, Inc., 315 Ga. 319, 355 (2022) ("Federal Defender I") is binding: “all members of the public” includes all ages and has no age limitation.
  • Contract construction: The Court construed “readily available” according to ordinary meaning—accessible/obtainable without much difficulty—and concluded nothing in that phrase requires FDA approval for every age group.
  • Summary judgment error: Given undisputed evidence of adequate vaccine supply and no legal prohibition on vaccination of any age if medically appropriate, the trial court erred in holding the Vaccine Condition unsatisfied.
  • Disposition: The Court reversed and remanded for further proceedings; it did not reach the State’s other claims of error (indefinite contract and overbroad injunction).

Justice Land concurred, emphasizing that the Agreement restricts only the Attorney General’s office from pursuing execution warrants from district attorneys and expressly recognizes that district attorneys retain “sole authority to obtain an execution warrant.”

3. Analysis

A. Precedents Cited

1) The prior controlling decision: “law of the case” from Federal Defender I

The Court treated its earlier construction in State v. Fed. Defender Program, Inc., 315 Ga. 319, 355 (2022) ("Federal Defender I") as binding. In that first appeal, the Court rejected the State’s argument that “all members of the public” should exclude young children, holding instead that the Agreement—drafted by the State—“places no limitation on the age of who is considered a member of the public.”

The State attempted to avoid that holding by characterizing it as interlocutory and record-dependent. The Court relied on Pirkle v. Turner, 281 Ga. 846, 846-47 (2007) to explain why purely legal determinations made during interlocutory review remain binding: no amount of new evidence changes a question of law. The Court grounded this approach in OCGA § 9-11-60(h).

2) PLRA appellate pathway: defining “action filed by a prisoner”

To decide whether OCGA § 42-12-8 required discretionary appeal, the Court applied text-first statutory interpretation principles, citing Deal v. Coleman, 294 Ga. 170, 172 (2013), State v. Islam, 321 Ga. 30, 32 (2025), and State v. Harris, 319 Ga. 665, 667 (2024). It then used civil-procedure doctrine to characterize intervention and the nature of “action.”

  • Undercofler v. Seaboard Air Line R. Co., 222 Ga. 822, 829 (1966), Todd v. Conner, 220 Ga. 173, 179 (1964), and O'Brien v. Builders Ins., 350 Ga. App. 77, 78 (2019) (quoting AC Corp. v. Myree, 221 Ga. App. 513, 515 (1996)) established the “true intervenor” principle: an intervenor “takes the case as he finds it” and cannot expand the litigation. This supported the Court’s conclusion that an intervenor does not “file” the underlying action.
  • State v. SASS Grp., LLC, 315 Ga. 893, 900-01 (2023) was used for the ordinary civil-litigation meaning of “action” as a whole lawsuit, reinforcing that an intervention motion is not itself an “action.”
  • The Court distinguished prior PLRA decisions relied on by appellees: Ray v. Barber, 273 Ga. 856 (2001) (later clarified by Brown v. Crawford, 289 Ga. 722, 725 (2011) to apply when a non-prisoner appeals an action originally filed by a prisoner); Griffin v. Keller, 278 Ga. 878 (2005) (prisoner filed the appeal); and Serpentfoot v. Salmon, 225 Ga. App. 478 (1997) (the prisoner’s filing initiated the proceeding rather than intervening in an existing one).

3) Summary judgment standards and evidentiary limits

The Court restated de novo review and the OCGA § 9-11-56(c) standard, citing Kaplan v. City of Sandy Springs, 286 Ga. 559, 560 (2010), and noting Sumter Co. v. Morris, 318 Ga. 1, 10 (2023) (disapproving Kaplan on other grounds). Critically, it enforced the rule that courts need not accept legal conclusions in affidavits: GE Cap. Mtg. Servs., Inc. v. Clack, 271 Ga. 82, 84 (1999) and Love v. Love, 259 Ga. 423, 424 (1989). This doctrine mattered because appellees’ expert offered a conclusory assertion that providers “cannot” vaccinate under-six-month infants due to lack of FDA authorization, without identifying a legal prohibition.

4) Contract construction methodology

The Court drew from a line of Georgia contract-interpretation decisions: State Auto Prop. and Cas. Co. v. Matty, 286 Ga. 611, 612 (2010) (cardinal rule—ascertain intent), Archer W. Contractors, Ltd. v. Estate of Pitts, 292 Ga. 219, 224 (2012) (ordinary meaning; dictionary use), and Langley v. MP Spring Lake, LLC, 307 Ga. 321, 325 (2019) (context matters; term not read in isolation). It also invoked the principle against judicial rewriting of contracts, citing Daniel v. Daniel, 250 Ga. 849, 851 (1983).

5) FDA regulation context and off-label use

While not essential to the holding (because the case turned on plain meaning), the opinion’s footnotes situated the FDA’s authority under federal law and noted that FDA approval for one indication permits marketing and prescribing flexibility, citing Iron-workers Local Union 68 v. AstraZeneca Pharms., LLC, 634 F3d 1352, 1356 n.5 (11th Cir. 2011). It also referenced Buckman Co. v. Plaintiffs' Legal Comm., 531 US 341, 350 (2001) to support the concept that “off-label” use is not prohibited by the FDA because it does not regulate the practice of medicine.

6) The concurrence on prosecutorial authority

Justice Land’s concurrence relied on McLaughlin v. Payne, 295 Ga. 609, 612 (2014) (quoting the Georgia Constitution) to underscore that district attorneys have constitutional duties in criminal cases. This frames the Agreement’s operational limits: it restricts the Attorney General’s office but does not restrain district attorneys who “maintain the sole authority to obtain an execution warrant.”

7) Other contextual citations

The opinion noted Presnell’s case history through Presnell v. State, 274 Ga. 246 (2001 ), cert. denied, 535 US 1 059 (2002), but that background did not drive the contract-interpretation holding.

B. Legal Reasoning

1) Jurisdiction: intervention does not convert the suit into a prisoner-filed “action”

The Court’s PLRA analysis has a clear logical sequence:

  1. OCGA § 42-12-8 mandates discretionary appeals only for “actions filed by prisoners.”
  2. Presnell did not initiate the lawsuit; he intervened in a suit filed by a non-prisoner entity.
  3. Under Georgia intervention doctrine, an intervenor takes the case as found and cannot inject new issues; therefore, intervention is not the filing of the action.
  4. Text and context of civil procedure (OCGA § 9-11-24) treat intervention as a motion within an existing action; “action” ordinarily means the entire lawsuit.
  5. Precedent applying the PLRA to non-prisoners is confined to appeals arising from actions originally filed by prisoners, which is not this case.

This reasoning narrows an expansive reading of PLRA appellate limitations and prevents a procedural “status change” (a prisoner’s later intervention) from altering the appeal route for all parties.

2) Law of the case: binding interpretation of “all members of the public”

The Court held that the phrase “all members of the public” includes all ages, including infants under six months. That conclusion was fixed by Federal Defender I and insulated from later factual development because it is a legal interpretation of contract text. The Court thus split the Vaccine Condition into two separate interpretive questions: (i) who must have access (“all members of the public,” already decided), and (ii) what level/type of access is required (“readily available,” decided here).

3) Plain meaning of “readily available” excludes an implied FDA-approval condition

The crux is the Court’s refusal to graft regulatory milestones onto contract language that does not reference them. The Court:

  • Defined “readily” and “available” using ordinary dictionaries to mean accessible/obtainable without much difficulty.
  • Applied Langley’s contextual approach but found no contractual context that imported FDA licensure/authorization as a textual requirement.
  • Enforced Daniel v. Daniel: courts must enforce contracts as written and cannot add terms.

In effect, the Court treated FDA approval as potentially relevant evidence about practical access in some cases, but not as a contractual prerequisite unless the contract says so.

4) No genuine dispute of material fact: availability turns on access, not recommendations

On the record, the Court identified:

  • Undisputed vaccine supply exceeding demand.
  • No identified statute/regulation prohibiting administration to under-six-month infants if requested and medically appropriate.
  • Expert testimony that most vaccines are not recommended for under-six-month infants—treated as a clinical guidance fact that may affect uptake, not a legal or practical bar to obtainability.

The Court also discounted appellees’ expert’s “cannot provide” statement as a legal conclusion unsupported by identified legal restrictions, applying Clack and Love. This evidentiary move was decisive: once the “FDA approval equals availability” premise fell away, the record lacked evidence of an actual prohibition or practical impossibility.

5) Remedy implications: reversal of injunction tied to erroneous construction

Because the trial court’s permanent injunction rested on its construction that the Vaccine Condition was unsatisfied, reversal of that construction undermined the injunction. The Court therefore reversed and remanded without addressing additional challenges (indefiniteness; breadth). The litigation may continue on other contractual conditions (the visitation condition was noted as not yet litigated).

C. Impact

1) Contract drafting and interpretation: “regulatory triggers” must be explicit

The decision’s most portable rule is interpretive: when parties intend regulatory approval (FDA, CDC, agency orders, etc.) to serve as a condition precedent, they must say so. Terms like “readily available” will be read as practical accessibility/obtainability, not as “fully approved,” “authorized,” or “licensed,” absent explicit text. This has implications beyond the death-penalty context, including contracts tied to public health resources, supply-chain restoration, licensing, and government reopening milestones.

2) Evidence on summary judgment: distinguish “medical guidance” from “legal impediment”

The Court’s treatment of expert assertions reinforces that on summary judgment a party must show concrete barriers—legal prohibitions or factual unavailability— not merely that something is not routinely recommended or commonly administered.

3) PLRA appellate practice: interventions do not reroute appeals into discretionary review

The jurisdiction holding meaningfully limits the PLRA’s reach: a prisoner’s later intervention in a non-prisoner-filed civil action does not transform the case into an “action filed by a prisoner” for purposes of OCGA § 42-12-8. This reduces incentives for jurisdictional gamesmanship and adds predictability in mixed-party litigation.

4) Execution-warrant mechanics: the concurrence highlights an enforcement boundary

Justice Land’s concurrence is a practical warning for the next phase of litigation: even a fully enforceable agreement with the Attorney General may not stop a district attorney acting independently, because the Agreement “places no restrictions on district attorneys” and recognizes their “sole authority to obtain an execution warrant.” Future disputes may pivot from “contract conditions” to “who is bound and what conduct is restrained,” including the proper tailoring of injunctive relief.

4. Complex Concepts Simplified

Law of the case
Once an appellate court decides a legal question in a case, that legal ruling generally binds the trial court and the appellate court in later stages of the same case. Here, the meaning of “all members of the public” (no age limit) was already decided in Federal Defender I.
Summary judgment
A pretrial decision where the court rules as a matter of law because there is no genuine dispute over material facts. The appellate court reviews it de novo (fresh, without deference).
Condition precedent (in a contract)
An event that must occur before a contractual duty becomes enforceable. The Vaccine Condition was a condition precedent to the Attorney General’s office pursuing execution warrants in covered cases.
Emergency Use Authorization (EUA) vs. full FDA approval/clearance
EUA is an expedited mechanism allowing use during emergencies based on a different evidentiary threshold than standard licensure. The Court treated the contract question as independent of whether authorization was EUA or full approval because the contract did not reference FDA status.
“Off-label” use
A physician’s use of an approved product in a way not specifically listed on the FDA-approved label. The opinion noted that FDA regulation generally does not prohibit physicians from such uses, supporting the conclusion that lack of a specific pediatric indication does not automatically equal legal unavailability.
Intervention
A procedure allowing a nonparty to join an existing lawsuit because they have an interest in the outcome. An intervenor “takes the case as he finds it” and does not become the filer of the lawsuit.

5. Conclusion

The Supreme Court of Georgia’s key contribution in this decision is a disciplined application of plain-meaning contract interpretation: “readily available” means practically obtainable without much difficulty, and courts may not transform that phrase into an implied FDA-approval-for-every-age-group requirement. Procedurally, the Court also clarified that a prisoner’s intervention does not convert a non-prisoner-filed suit into a prisoner-filed “action” under the PLRA for appellate-routing purposes.

On remand, the parties’ broader dispute over the Agreement’s remaining conditions, notice obligations, and the scope of any injunctive relief will proceed under the Court’s clarified construction, with Justice Land’s concurrence spotlighting a structural limitation: the Agreement constrains the Attorney General’s pursuit of warrants but does not, by its own terms, bind district attorneys.